Nexviazyme

Summary : Two-year data shows Pompe disease patients treated with Nexviazyme® (avalglucosidase alfa) have sustained improvements in respiratory function and mobility. Sanofi has…

US FDA’s Center for Drug Evaluation and Research (CDER) – Novel Drug Approvals for 2021 Innovation drives progress. When it comes to…